Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China
· Delayed Price · Currency is CNY 50.31
+1.58 (3.24%)
Apr 29, 2026, 3:00 PM CST
SHA:603334 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Operating Revenue | 3,164 | 1,945 | 1,726 | 1,704 | 1,292 | Upgrade
|
| Other Revenue | 6.57 | 2.82 | 2.07 | 4.44 | 3.11 | Upgrade
|
| Revenue | 3,171 | 1,948 | 1,728 | 1,709 | 1,296 | Upgrade
|
| Revenue Growth (YoY) | 62.77% | 12.75% | 1.12% | 31.89% | 64.04% | Upgrade
|
| Cost of Revenue | 2,914 | 1,721 | 1,489 | 1,478 | 1,101 | Upgrade
|
| Gross Profit | 256.3 | 226.71 | 238.43 | 230.89 | 195.08 | Upgrade
|
| Selling, General & Admin | 58.25 | 50.88 | 56.84 | 41.13 | 36.24 | Upgrade
|
| Research & Development | 68.18 | 53.57 | 58.57 | 51.35 | 41.88 | Upgrade
|
| Other Operating Expenses | -30.41 | -8.24 | -16.7 | -6.63 | -5.9 | Upgrade
|
| Operating Expenses | 98.82 | 100.76 | 95.55 | 87.74 | 73.79 | Upgrade
|
| Operating Income | 157.48 | 125.95 | 142.89 | 143.15 | 121.29 | Upgrade
|
| Interest Expense | -7.69 | -6 | -7.12 | -6.28 | -3.35 | Upgrade
|
| Interest & Investment Income | 1.2 | 1.01 | 2.93 | 0.63 | 2.31 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | 4.65 | 2.71 | 9.87 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1.79 | -0.92 | -4.7 | -0.68 | -3.05 | Upgrade
|
| EBT Excluding Unusual Items | 149.09 | 124.69 | 136.72 | 146.69 | 117.19 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.42 | -0.34 | -4.02 | -5.03 | -0.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.38 | -0.01 | 0.02 | -0.06 | -0.41 | Upgrade
|
| Asset Writedown | - | - | -0.76 | -1.7 | -0.54 | Upgrade
|
| Legal Settlements | - | - | - | - | -1 | Upgrade
|
| Other Unusual Items | 4.35 | 10.09 | 12.45 | 3.58 | -6.1 | Upgrade
|
| Pretax Income | 153.5 | 134.42 | 144.41 | 143.47 | 108.42 | Upgrade
|
| Income Tax Expense | 12.97 | 10.6 | 14.7 | 10.12 | 6.38 | Upgrade
|
| Earnings From Continuing Operations | 140.53 | 123.82 | 129.71 | 133.35 | 102.03 | Upgrade
|
| Minority Interest in Earnings | 0.03 | - | - | -0 | -0.12 | Upgrade
|
| Net Income | 140.55 | 123.82 | 129.71 | 133.35 | 101.91 | Upgrade
|
| Net Income to Common | 140.55 | 123.82 | 129.71 | 133.35 | 101.91 | Upgrade
|
| Net Income Growth | 13.51% | -4.54% | -2.73% | 30.85% | 107.98% | Upgrade
|
| Shares Outstanding (Basic) | 113 | 108 | 107 | 106 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 113 | 108 | 107 | 106 | 106 | Upgrade
|
| Shares Change (YoY) | 5.28% | 0.44% | 1.29% | -0.31% | 6.16% | Upgrade
|
| EPS (Basic) | 1.24 | 1.15 | 1.21 | 1.26 | 0.96 | Upgrade
|
| EPS (Diluted) | 1.24 | 1.15 | 1.21 | 1.26 | 0.96 | Upgrade
|
| EPS Growth | 7.83% | -4.96% | -3.97% | 31.25% | 95.92% | Upgrade
|
| Free Cash Flow | -50.8 | -57.1 | -5.62 | -10.38 | 5.01 | Upgrade
|
| Free Cash Flow Per Share | -0.45 | -0.53 | -0.05 | -0.10 | 0.05 | Upgrade
|
| Dividend Per Share | 0.350 | - | - | - | - | Upgrade
|
| Gross Margin | 8.08% | 11.64% | 13.80% | 13.51% | 15.06% | Upgrade
|
| Operating Margin | 4.97% | 6.46% | 8.27% | 8.38% | 9.36% | Upgrade
|
| Profit Margin | 4.43% | 6.36% | 7.51% | 7.80% | 7.87% | Upgrade
|
| Free Cash Flow Margin | -1.60% | -2.93% | -0.33% | -0.61% | 0.39% | Upgrade
|
| EBITDA | 185.48 | 142.17 | 155.76 | 154.31 | 131.2 | Upgrade
|
| EBITDA Margin | 5.85% | 7.30% | 9.01% | 9.03% | 10.13% | Upgrade
|
| D&A For EBITDA | 28 | 16.23 | 12.87 | 11.16 | 9.91 | Upgrade
|
| EBIT | 157.48 | 125.95 | 142.89 | 143.15 | 121.29 | Upgrade
|
| EBIT Margin | 4.97% | 6.46% | 8.27% | 8.38% | 9.36% | Upgrade
|
| Effective Tax Rate | 8.45% | 7.89% | 10.18% | 7.05% | 5.89% | Upgrade
|
| Revenue as Reported | 3,171 | 1,948 | 1,728 | 1,709 | - | Upgrade
|
| Advertising Expenses | 0.3 | 0.43 | 0.46 | 0.2 | 0.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.